MAPT and Alzheimer disease: We next tested whether the subtypes differed in their risk to develop AD pathology, by estimating changes over time in CSF Aβ42 and p181-tau levels, which was available in ADNI only (n = 45, mean ± SD 3.2 ± 1.2 repeated samples over mean ± SD 3 ± 1.9 years).